SCHEMBL3119210

SCHEMBL3119210

CCCCN(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)C(=O)Nc1ccccc1OCC

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.50
HDAC1 Q13547 6/20 0.50
HDAC3 O15379 3/20 0.50
HDAC2 Q92769 3/20 0.50
HDAC8 Q9BY41 2/20 0.50
AGTR1 P30556 9/20 0.42
AGTR2 P50052 8/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LTB4R2 Q9NPC1 3/20 0.41
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3124333 0.89 LTB4R2 (0.46) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3121577 0.88 HDAC6 (0.44) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3127930 0.87 HDAC6 (0.46) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3117065 0.87 MAPT (0.50) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL5057773 0.86 HDAC6 (0.43) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3117096 0.85 HDAC6 (0.56) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL5062923 0.84 HDAC6 (0.42) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3124799 0.84 HDAC6 (0.49) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3121370 0.84 HDAC6 (0.52) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL5061635 0.83 ALDH1A1 (0.43) HDAC6HDAC1HDAC3HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673889-B2 BLT2-mediated disease, BLT2 binding agent and the compound ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-18 US disclosed
EP-2172222-A2 Novel BLT2-mediated disease, BLT2-binding agent and compound ONO PHARMACEUTICAL CO., LTD. (JP) 2010-04-07 EP disclosed
US-20080132574-A1 Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-05 US disclosed
EP-1745800-A1 NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132574-A1 Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound MALT1, SLC10A2, LCP2 HDAC6 1723/4885HDAC1 443/4885HDAC3 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.